British pharmaceuticals giant GlaxoSmithKline is set to announce that it would be able to produce millions of doses of a vaccine against bird flu within four months of the declaration of a pandemic. The group will make the announcement on Thursday when it presents its quarterly results, the Sunday Times report said.GlaxoSmithKline produces Relenza, an antiviral oral spray that is far less popular than the sought-after Tamiflu tablet treatment produced by Swiss rival Roche. Neither drug is a cure for influenza, but they reduce the impact of the virus.Britain’s chief medical officer Sir Liam Donaldson said last week that 120 million doses -- the equivalent of two doses for every man, woman and child in the country -- would be needed to cover the entire population.
